(Q37575167)

English

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

scientific article published on 31 October 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (English)

1 reference

Europe PubMed Central

21 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

object named as

Michael Untch

0 references

1

object named as

Nadia Harbeck

0 references

Matthias W. Beckmann

19

object named as

Matthias W Beckmann

1 reference

Europe PubMed Central

21 August 2017

author name string

Steffen Saupe

2

1 reference

Europe PubMed Central

21 August 2017

Elke Jäger

3

1 reference

Europe PubMed Central

21 August 2017

Marcus Schmidt

4

1 reference

Europe PubMed Central

21 August 2017

Rolf Kreienberg

5

1 reference

Europe PubMed Central

21 August 2017

Lothar Müller

6

1 reference

Europe PubMed Central

21 August 2017

Burkhard Joerg Otremba

7

1 reference

Europe PubMed Central

21 August 2017

Dirk Waldenmaier

8

1 reference

Europe PubMed Central

21 August 2017

Julia Dorn

9

1 reference

Europe PubMed Central

21 August 2017

Mathias Warm

10

1 reference

Europe PubMed Central

21 August 2017

Michael Scholz

11

1 reference

Europe PubMed Central

21 August 2017

Maike de Wit

13

1 reference

Europe PubMed Central

21 August 2017

Jana Barinoff

14

1 reference

Europe PubMed Central

21 August 2017

Hans-Joachim Lück

15

1 reference

Europe PubMed Central

21 August 2017

Philipp Harter

16

1 reference

Europe PubMed Central

21 August 2017

Doris Augustin

17

1 reference

Europe PubMed Central

21 August 2017

Paul Harnett

18

1 reference

Europe PubMed Central

21 August 2017

Salah-Eddin Al-Batran

20

1 reference

Europe PubMed Central

21 August 2017

PELICAN Investigators

21

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

31 October 2016

1 reference

Europe PubMed Central

21 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

21 August 2017

161

1 reference

Europe PubMed Central

21 August 2017

1

1 reference

Europe PubMed Central

21 August 2017

63-72

1 reference

Europe PubMed Central

21 August 2017

copyright license

Creative Commons Attribution 4.0 International

31 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s10549-016-4033-3

0 references

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

23 August 2017

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

25 June 2018

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

1 September 2018

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

1 September 2018

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

1 September 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

1 September 2018

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

1 September 2018

Cochrane Database of Systematic Reviews

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4033-3

21 January 2018

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5222915

2 October 2018

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4033-3

21 January 2018

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4033-3

21 January 2018

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27798749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27798749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-016-4033-3

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37575167&oldid=1850133016"